A new class of cancer-associated PTEN mutations defined by membrane translocation defects

Oncogene

Volumn 34, Issue 28, 2015, Pages 3737-3743

  Nguyen, H N ^a   Yang, J M ^a   Rahdar, M ^a   Keniry, M ^b,d   Swaney, K F ^a   Parsons, R ^b   Park, B H ^c   Sesaki, H ^a   Devreotes, P N ^a   Iijima, M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS PAN AMERICAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE A4; UNCLASSIFIED DRUG; PHOSPHATIDYLINOSITOL 3,4,5-TRIPHOSPHATE; POLYPHOSPHOINOSITIDE; PTEN PROTEIN, HUMAN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL MEMBRANE; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MEMBRANE BINDING; MISSENSE MUTATION; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; DICTYOSTELIUM; GENETICS; HEK293 CELL LINE; METABOLISM; NEOPLASM; PHOSPHORYLATION; PROTEIN TRANSPORT; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MEMBRANE; DICTYOSTELIUM; HEK293 CELLS; HUMANS; NEOPLASMS; PHOSPHATIDYLINOSITOL PHOSPHATES; PHOSPHORYLATION; PROTEIN TRANSPORT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION;

EID: 84938512401     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.293     Document Type: Article

References (34)

1. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 2009; 4: 127-150.
2. Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC1 gene: A tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 1999; 91: 1922-1932.
3. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012; 18: 400-407.
4. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011; 11: 289-301.
5. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012; 13: 283-296.
6. Leslie NR, Batty IH, Maccario H, Davidson L, Downes CP. Understanding PTEN regulation: PIP2, polarity and protein stability. Oncogene 2008; 27: 5464-5476.
7. Denning G, Jean-Joseph B, Prince C, Durden DL, Vogt PK. A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth. Oncogene 2007; 26: 3930-3940.
8. Han SY, Kato H, Kato S, Suzuki T, Shibata H, Ishii S et al. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res 2000; 60: 3147-3151.
9. Rodriguez-Escudero I, Oliver MD, Andres-Pons A, Molina M, Cid VJ, Pulido R. A comprehensive functional analysis of PTEN mutations: Implications in tumor-and autism-related syndromes. Hum Mol Genet 2011; 20: 4132-4142.
10. Nguyen HN, Afkari Y, Senoo H, Sesaki H, Devreotes PN, Iijima M. Mechanism of human PTEN localization revealed by heterologous expression in Dictyostelium. Oncogene 2014; 33: 5688-5696.
11. Rahdar M, Inoue T, Meyer T, Zhang J, Vazquez F, Devreotes PN. A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. Proc Natl Acad Sci USA 2009; 106: 480-485.
12. Gericke A, Leslie NR, Losche M, Ross AH. PtdIns(4,5)P2-mediated cell signaling: Emerging principles and PTEN as a paradigm for regulatory mechanism. Adv Exp Med Biol 2013; 991: 85-104.
13. Das S, Dixon JE, Cho W. Membrane-binding and activation mechanism of PTEN. Proc Natl Acad Sci USA 2003; 100: 7491-7496.
14. Keniry M, Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008; 27: 5477-5485.
15. Vazquez F, Matsuoka S, Sellers WR, Yanagida T, Ueda M, Devreotes PN. Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane. Proc Natl Acad Sci USA 2006; 103: 3633-3638.
16. Nguyen HN, Yang JM, Afkari Y, Park BH, Sesaki H, Devreotes PN et al. Engineering ePTEN, an enhanced PTEN with increased tumor suppressor activities. Proc Natl Acad Sci USA 2014; 111: E2684-E2693.
17. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 2000; 20: 5010-5018.
18. Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and-independent mechanisms. Cancer Cell 2003; 3: 117-130.
19. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y et al. Regulation of PTEN transcription by p53. Mol Cell 2001; 8: 317-325.
20. Iijima M, Devreotes P. Tumor suppressor PTEN mediates sensing of chemoattractant gradients. Cell 2002; 109: 599-610.
21. Iijima M, Huang YE, Devreotes P. Temporal and spatial regulation of chemotaxis. Dev Cell 2002; 3: 469-478.
22. Hawkins PT, Anderson KE, Davidson K, Stephens LR. Signalling through Class I PI3Ks in mammalian cells. Biochem Soc Trans 2006; 34(Pt 5): 647-662.
23. Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP et al. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci USA 2009; 106: 2835-2840.
24. Wang GM, Wong HY, Konishi H, Blair BG, Abukhdeir AM, Gustin JP et al. Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Res 2013; 73: 3248-3261.
25. Kamimura Y, Xiong Y, Iglesias PA, Hoeller O, Bolourani P, Devreotes PN. PIP3-independent activation of TorC2 and PKB at the cell's leading edge mediates chemotaxis. Curr Biol 2008; 18: 1034-1043.
26. Chen CL, Wang Y, Sesaki H, Iijima M. Myosin I links PIP3 signaling to remodeling of the actin cytoskeleton in chemotaxis. Sci Signal 2012; 5: Ra10.
27. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004; 91: 355-358.
28. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y et al. Crystal structure of the PTEN tumor suppressor: Implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999; 99: 323-334.
29. Wang Y, Senoo H, Sesaki H, Iijima M. Rho GTPases orient directional sensing in chemotaxis. Proc Natl Acad Sci USA 2013; 110: E4723-E4732.
30. Zhang P, Wang Y, Sesaki H, Iijima M. Proteomic identification of phosphatidylinositol (3,4,5) triphosphate-binding proteins in Dictyostelium discoideum. Proc Natl Acad Sci USA 2010; 107: 11829-11834.
31. Kim JS, Xu X, Li H, Solomon D, Lane WS, Jin T et al. Mechanistic analysis of a DNA damage-induced, PTEN-dependent size checkpoint in human cells. Mol Cell Biol 2011; 31: 2756-2771.
32. Cai H, Huang CH, Devreotes PN, Iijima M. Analysis of chemotaxis in Dictyostelium. Methods Mol Biol 2012; 757: 451-468.
33. Wang Y, Steimle PA, Ren Y, Ross CA, Robinson DN, Egelhoff TT et al. Dictyostelium huntingtin controls chemotaxis and cytokinesis through the regulation of myosin II phosphorylation. Mol Biol Cell 2011; 22: 2270-2281.
34. Iijima M, Huang YE, Luo HR, Vazquez F, Devreotes PN. Novel mechanism of PTEN regulation by its phosphatidylinositol 4,5-bisphosphate binding motif is critical for chemotaxis. J Biol Chem 2004; 279: 16606-16613.